CHICAGO, AUGUST 25, 2020 — The Clinical trials investigating 16 promising therapies for Alzheimer’s and dementia are taking off thanks to $24 million in new grant funding from the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates.
- T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer’s Disease
- T3D Therapeutics Receives a Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
- Alzheimer’s Association Part The Cloud Grant Program Invests $24 Million in 16 Innovative Research Trials
- Leading Alzheimer’s Disease Experts Join T3D Therapeutics’ Scientific Advisory Board
- T3D Therapeutics Begins Enrollment in the PIONEER Phase 2 Clinical Trial of T3D-959 in Patients with Mild to Moderate Alzheimer’s Disease